The animal, which was obtained from a local farm in June 2003, was part of a herd of 23 goats on an IACUC-approved protocol as antibody producers. The herd was open-source and positive for caseous lymphadenitis. The herd's serologic status for caprine arthritis-encephalitis (CAE) virus was unknown, but suspected to be positive. The herd was maintained on a five-acre pasture and supplemented the diet with a grain mix that had a guaranteed crude protein and fat of 18.0% and 3.5%, respectively. The goats were dewormed quarterly with alternating anthelmintics.
Before introduction to the herd, we examined the goat, administered Clostridium perfringens Type C & D vaccination (Boehringer Ingelheim Vetmedica, Inc., St. Joseph, MO) to protect against Clostridial enterotoxemia, dewormed with injectable ivermectin (MSD-AgVet Division, Merck, Norwalk, CT), and trimmed its hooves. The animal appeared to be in good health. After the goat's introduction to the herd, we dewormed it again in August and October 2003 with albendazole (Pfizer, New York, NY) and in January, March, August, and November 2004 with ivermectin (MSD-AgVet Division, Merck). We also trimmed its hooves in March and June 2004. In March 2004, we gave the goat additional vaccinations for Orf virus (the cause of contagious ecthyma or scabby mouth), Clostridium tetani (the cause of tetanus), and Clostridium perfringens Types C & D (Boehringer Ingelheim Vetmedica, Inc.). In August 2004, the animal presented with right hind limb lameness. We noticed that the front knees were slightly subluxated. We placed the goat on the anti-inflammatory and analgesic drug ketoprofen (Merial, Duluth, GA) at a dose of 1 ml/33 kg i.m. once a day for three days.
This is a preview of subscription content, access via your institution
